OR WAIT null SECS
March 27, 2020
ProBioGen will facilitate the development of Immunogenesis’ monoclonal antibody candidate and will be responsible for manufacturing the drug at its new facility in Berlin, Germany.
The companies will use CytomX’s Probody therapeutic technology platform and its proprietary bispecific formats and CD3 modules.
AstraZeneca has announced that it has achieved approval in Japan for Lokelma (sodium zirconium cyclosilicate) for the treatment of patients with hyperkalemia (elevated blood potassium levels).
Mylan and Pfizer announced a postponement of the transaction that would see Mylan and Upjohn Combined until the second half of the year as a result of the current COVID-19 pandemic.
AstraZeneca has revealed that it will collaborate with Silence Therapeutics on the discovery, development, and commercialization of small interfering RNA (siRNA) therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases.
Grifols has entered into a formal collaboration with US Federal public health agencies, including the Biomedical Advanced Research Development Authority (BARDA) and the Food and Drug Administration (FDA), to produce a treatment that specifically targets COVID-19.
The strategic alliance provides an integrated product offering around drug discovery and development.
The company has developed mathematical algorithms that generate simple cell-count data from a few days of culture.
The new NAB Nanosep device provides increased binding capacity.
The company has launched new high volume eight- and 12-channel pipettes, offering a capacity of 1250 µL per channel.